Autor(es): Aggarwal Megha, Sharma Rajesh, Kumar Pravindra, Parida Manmohan, Tomar Shailly

Resumo: Chikungunya virus (CHIKV) capsid protein (CVCP) is a serine protease that possesses cis-proteolytic activity essential for the structural polyprotein processing - plays a key role in the virus life cycle. CHIKV being an emerging arthropod-borne pathogenic virus, is a public health concern worldwide. No vaccines or specific antiviral treatment is currently available for chikungunya disease. Thus, it is important to develop inhibitors against CHIKV enzymes to block key steps in viral reproduction. In view of this, CVCP was produced recombinantly - purified to homogeneity. A fluorescence resonance energy transfer (FRET)-based proteolytic assay was developed for high throughput screening (HTS). A FRET peptide substrate (DABCYL-GAEEWSLAIE-EDANS) derived from the cleavage site present in the structural polyprotein of CVCP was used. The assay with a Z' factor of 0.64 - coefficient of variation (CV) is 8.68% can be adapted to high throughput format for automated screening of chemical libraries to identify CVCP specific protease inhibitors. Kinetic parameters Km - kcat/Km estimated using FRET assay were 1.26 ± 0.34 ?M - 1.11 × 10(3) M(-1) sec(-1) respectively. The availability of active recombinant CVCP - cost effective fluorogenic peptide based in vitro FRET assay may serve as the basis for therapeutics development against CHIKV.

Imprenta: Scientific Reports, v. 5, p. 14753, 2015

Identificador do objeto digital: 10.1038/srep14753

Descritores: Chikungunya Virus - Virus ; Chikungunya virus - Vaccine ; Chikungunya virus - Public health

Data de publicação: 2015

INDICADORES

ACESSO